193 related articles for article (PubMed ID: 24025360)
1. The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity.
Lin J; Spidel JL; Maddage CJ; Rybinski KA; Kennedy RP; Krauthauser CL; Park YC; Albone EF; Jacob S; Goserud MT; Martinez BP; Chao Q; Zhou Y; Nicolaides NC; Kline JB; Grasso L
Cancer Biol Ther; 2013 Nov; 14(11):1032-8. PubMed ID: 24025360
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer.
Wen Y; Graybill WS; Previs RA; Hu W; Ivan C; Mangala LS; Zand B; Nick AM; Jennings NB; Dalton HJ; Sehgal V; Ram P; Lee JS; Vivas-Mejia PE; Coleman RL; Sood AK
Clin Cancer Res; 2015 Jan; 21(2):448-59. PubMed ID: 25416196
[TBL] [Abstract][Full Text] [Related]
3. The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.
Estupina P; Fontayne A; Barret JM; Kersual N; Dubreuil O; Le Blay M; Pichard A; Jarlier M; Pugnière M; Chauvin M; Chardès T; Pouget JP; Deshayes E; Rossignol A; Abache T; de Romeuf C; Terrier A; Verhaeghe L; Gaucher C; Prost JF; Pèlegrin A; Navarro-Teulon I
Oncotarget; 2017 Jun; 8(23):37061-37079. PubMed ID: 28427157
[TBL] [Abstract][Full Text] [Related]
4. Farletuzumab in lung cancer.
Thomas A; Maltzman J; Hassan R
Lung Cancer; 2013 Apr; 80(1):15-8. PubMed ID: 23357463
[TBL] [Abstract][Full Text] [Related]
5. FCGR2A and FCGR3A Genotypes Correlate with Farletuzumab Response in Patients with First-Relapsed Ovarian Cancer Exhibiting Low CA125.
Wang W; Somers EB; Ross EN; Kline JB; O'Shannessy DJ; Schweizer C; Weil S; Grasso L; Nicolaides NC
Cytogenet Genome Res; 2017; 152(4):169-179. PubMed ID: 29041009
[TBL] [Abstract][Full Text] [Related]
6. Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study.
Konner JA; Bell-McGuinn KM; Sabbatini P; Hensley ML; Tew WP; Pandit-Taskar N; Vander Els N; Phillips MD; Schweizer C; Weil SC; Larson SM; Old LJ
Clin Cancer Res; 2010 Nov; 16(21):5288-95. PubMed ID: 20855460
[TBL] [Abstract][Full Text] [Related]
7. Improved Intraoperative Detection of Ovarian Cancer by Folate Receptor Alpha Targeted Dual-Modality Imaging.
Hekman MCH; Boerman OC; Bos DL; Massuger LFAG; Weil S; Grasso L; Rybinski KA; Oosterwijk E; Mulders PFA; Rijpkema M
Mol Pharm; 2017 Oct; 14(10):3457-3463. PubMed ID: 28826214
[TBL] [Abstract][Full Text] [Related]
8. Farletuzumab in epithelial ovarian carcinoma.
Spannuth WA; Sood AK; Coleman RL
Expert Opin Biol Ther; 2010 Mar; 10(3):431-7. PubMed ID: 20092424
[TBL] [Abstract][Full Text] [Related]
9. Folate receptor α increases chemotherapy resistance through stabilizing MDM2 in cooperation with PHB2 that is overcome by MORAb-202 in gastric cancer.
Sakai H; Kawakami H; Teramura T; Onodera Y; Somers E; Furuuchi K; Uenaka T; Kato R; Nakagawa K
Clin Transl Med; 2021 Jun; 11(6):e454. PubMed ID: 34185411
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha.
Ebel W; Routhier EL; Foley B; Jacob S; McDonough JM; Patel RK; Turchin HA; Chao Q; Kline JB; Old LJ; Phillips MD; Nicolaides NC; Sass PM; Grasso L
Cancer Immun; 2007 Mar; 7():6. PubMed ID: 17346028
[TBL] [Abstract][Full Text] [Related]
11. Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer.
Bergamini A; Ferrero S; Leone Roberti Maggiore U; Scala C; Pella F; Vellone VG; Petrone M; Rabaiotti E; Cioffi R; Candiani M; Mangili G
Expert Opin Investig Drugs; 2016 Dec; 25(12):1405-1412. PubMed ID: 27797594
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer.
Farrell C; Schweizer C; Wustner J; Weil S; Namiki M; Nakano T; Nakai K; Phillips MD
Cancer Chemother Pharmacol; 2012 Nov; 70(5):727-34. PubMed ID: 22955257
[TBL] [Abstract][Full Text] [Related]
13. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.
Armstrong DK; White AJ; Weil SC; Phillips M; Coleman RL
Gynecol Oncol; 2013 Jun; 129(3):452-8. PubMed ID: 23474348
[TBL] [Abstract][Full Text] [Related]
14. Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro.
Kamen BA; Smith AK
Cancer Chemother Pharmacol; 2012 Jul; 70(1):113-20. PubMed ID: 22644798
[TBL] [Abstract][Full Text] [Related]
15. Farletuzumab, a monoclonal antibody directed against folate receptor alpha, shows no evidence of teratogenicity in cynomolgus monkeys.
Moriyama T; Kakiuchi D; Grasso L; Hutto DL; Fernando D; Schweizer C
Reprod Toxicol; 2018 Aug; 79():89-95. PubMed ID: 29928988
[TBL] [Abstract][Full Text] [Related]
16. Role of farletuzumab in epithelial ovarian carcinoma.
Jelovac D; Armstrong DK
Curr Pharm Des; 2012; 18(25):3812-5. PubMed ID: 22591419
[TBL] [Abstract][Full Text] [Related]
17. Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-γ receptor engagement.
Kline JB; Kennedy RP; Albone E; Chao Q; Fernando S; McDonough JM; Rybinski K; Wang W; Somers EB; Schweizer C; Grasso L; Nicolaides NC
Oncotarget; 2017 Aug; 8(32):52045-52060. PubMed ID: 28881712
[TBL] [Abstract][Full Text] [Related]
18. MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity.
Cheng X; Li J; Tanaka K; Majumder U; Milinichik AZ; Verdi AC; Maddage CJ; Rybinski KA; Fernando S; Fernando D; Kuc M; Furuuchi K; Fang F; Uenaka T; Grasso L; Albone EF
Mol Cancer Ther; 2018 Dec; 17(12):2665-2675. PubMed ID: 30262588
[TBL] [Abstract][Full Text] [Related]
19. Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers.
Oshima T; Sato S; Kato J; Ito Y; Watanabe T; Tsuji I; Hori A; Kurokawa T; Kokubo T
Mol Cancer; 2013 Jun; 12():60. PubMed ID: 23758976
[TBL] [Abstract][Full Text] [Related]
20. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models.
Ponte JF; Ab O; Lanieri L; Lee J; Coccia J; Bartle LM; Themeles M; Zhou Y; Pinkas J; Ruiz-Soto R
Neoplasia; 2016 Dec; 18(12):775-784. PubMed ID: 27889646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]